Biogen Inc (BIIB)

Pretax margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	1,906,000	1,906,900	1,314,900	1,322,600	1,296,400	1,608,700	3,120,600	3,688,900	3,679,700	3,886,400	2,818,800	1,583,500	1,608,500	1,168,300	1,807,300	3,756,100	4,992,800	6,337,400	7,152,300	6,906,300
Revenue (ttm)	US$ in thousands	9,675,900	9,607,500	9,672,000	9,663,100	9,835,600	9,993,300	9,971,500	10,104,600	10,173,400	10,363,200	10,633,600	10,819,500	10,981,700	11,100,500	11,697,700	12,604,300	13,444,600	14,263,300	14,487,300	14,422,400
Pretax margin		19.70%	19.85%	13.59%	13.69%	13.18%	16.10%	31.30%	36.51%	36.17%	37.50%	26.51%	14.64%	14.65%	10.52%	15.45%	29.80%	37.14%	44.43%	49.37%	47.89%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $1,906,000K ÷ $9,675,900K
= 19.70%

Biogen Inc's pretax margin has shown fluctuations over the years, ranging from a high of 49.37% in June 2020 to a low of 10.52% in September 2021. The pretax margin steadily declined from March 2021 to March 2022, hitting a low of 10.52% in September 2021 before recovering to 37.50% in September 2022. However, the margin then decreased again to 13.18% by December 2023 before showing a slight uptick to 19.70% in December 2024.

The pretax margin measures the company's efficiency in generating profits before accounting for taxes and is influenced by factors such as revenue, operating expenses, and tax rates. The fluctuations in Biogen Inc's pretax margin reflect changes in its profitability and cost management over the years. Investors and analysts may closely monitor this ratio to assess the company's ability to control costs and generate profits, which are critical factors in evaluating its financial health and performance.